Associated tags: Cell, HLHS, Metabolic syndrome, Hypoplastic left heart syndrome, Frailty, Ageing, Disorder, Bone marrow, Microsoft Exchange Server
Locations: MIAMI, FL, US, NV, AD, JAPAN, PARK AVENUE, NEW YORK, PHILADELPHIA, PA, USA, UNITED STATES, ARDS
MIAMI, June 10, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Emerging Growth Virtual Conference taking place June 12-13, 2024.
Key Points:
- MIAMI, June 10, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Emerging Growth Virtual Conference taking place June 12-13, 2024.
- Details for the Company’s presentation:
The webcast for this conference presentation may be accessed at the “ Events and Presentations ” section of the Company’s website.
- A replay of the webcast will be available on the Longeveron website for 180 days following the conference.
- Questions may be submitted in advance to [email protected] or asked during the event.
Ageing,
Patient,
Bangladesh Technical Education Board,
Cost,
Amnesia,
Patent,
Food,
COVID-19,
Heart,
Clinical trial,
FDA,
Vaccine,
Death,
Research,
CLEAR,
Lung,
Stem cell,
NHLBI,
Mortality,
Priority review,
BLA,
Administration,
Hypoplastic left heart syndrome,
Development,
NIH,
Pharmaceutical industry MIAMI, May 14, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today reported financial results for the quarter ended March 31, 2024 and provided a business update.
Key Points:
- MIAMI, May 14, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today reported financial results for the quarter ended March 31, 2024 and provided a business update.
- Grant revenue for the three months ended March 31, 2024 and 2023 was $0 and less than $0.1 million, respectively.
- Related cost of revenues: Cost of revenues was $0.2 million for the three-month periods ended March 31, 2024 and 2023.
- Other Expense (Income), net: Other income for the three months ended March 31, 2024 was less than $0.1 million.
MIAMI, April 25, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Planet MicroCap Showcase, taking place May 1-2, 2024.
Key Points:
- An archived replay of the webcast will be available on the “ Events & Presentations ” section of the Company’s website following the conference.
- If you would like to book 1x1 investor meetings with Longeveron Inc. and to attend the Planet MicroCap Showcase: VEGAS 2024, please register here: https://planetmicrocapshowcase.com/signup .
- 1x1 meetings will be scheduled and conducted in person at the conference venue: Paris Hotel & Casino in Las Vegas, NV.
Sale,
Regulation D,
Form S-1,
NOS,
Security (finance),
Hypoplastic left heart syndrome,
Exchange,
Public expenditure,
Form,
Exercise,
HLHS,
Clinical trial H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Key Points:
- H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
- The new warrants are immediately exercisable at an exercise price of $2.35 per share.
- The gross proceeds to the Company from the warrant exercise offering were approximately $6.2 million, prior to deducting placement agent fees and offering expenses payable by the Company.
- The total gross proceeds to the Company from the two offerings, this warrant exercise offering and the previously announced public offering, with gross proceeds of approximately $5.2 million, which closed on April 10, 2024, in each case, prior to deducting placement agent fees and offering expenses payable by the Company, were approximately $11.4 million.
Retrieved on:
Wednesday, April 17, 2024
Sale,
Regulation D,
Form S-1,
NOS,
Security (finance),
Hypoplastic left heart syndrome,
Exchange,
Public expenditure,
Form,
Exercise,
HLHS The issuance or resale of the shares of Class A common stock issuable upon exercise of the existing warrants, as applicable, are registered pursuant to effective registration statements on Form S-1 (File Nos.
Key Points:
- The issuance or resale of the shares of Class A common stock issuable upon exercise of the existing warrants, as applicable, are registered pursuant to effective registration statements on Form S-1 (File Nos.
- The gross proceeds to the Company from the exercise of the existing warrants are expected to be approximately $6.2 million, prior to deducting placement agent fees and estimated offering expenses payable by the Company.
- In consideration for the immediate exercise of the existing warrants for cash and the payment of $0.125 per new warrant, the Company will issue new unregistered warrants to purchase up to an aggregate of 4,799,488 shares of Class A common stock.
- The new warrants will be immediately exercisable at an exercise price of $2.35 per share.
MIAMI, April 15, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it has been accepted for a Featured Research Oral Presentation to present the Company’s CLEAR MIND Phase 2a study results.
Key Points:
- MIAMI, April 15, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it has been accepted for a Featured Research Oral Presentation to present the Company’s CLEAR MIND Phase 2a study results.
- CLEAR-MIND is a Phase 2a randomized clinical trial evaluating Lomecel-B TM in mild Alzheimer’s Disease.
- In addition to the clinical study results, the Company has been accepted for a poster presentation at the 2024 Alzheimer’s Association International Conference (AAIC) , to be held July 28 – August 1, 2024 in Philadelphia, PA, USA and online.
- “We are extremely excited to share the full study results of our CLEAR-MIND trial at the AAIC meeting this year, and have the opportunity to present at the leading forum for Alzheimer’s disease clinical investigation,” said Wa’el Hashad , CEO of Longeveron.
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Key Points:
- H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
- The gross proceeds to the Company from the offering were approximately $5.2 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.
- Certain board members and insiders of the Company participated in the offering in an aggregate amount of approximately $700,000, at the same terms and conditions.
- The offering was made only by means of a prospectus, which forms a part of the effective registration statement.
The closing of the offering is expected to occur on or about April 10, 2024, subject to the satisfaction of customary closing conditions.
Key Points:
- The closing of the offering is expected to occur on or about April 10, 2024, subject to the satisfaction of customary closing conditions.
- The gross proceeds to the Company from the offering are expected to be approximately $5.25 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.
- The offering is being made only by means of a prospectus, which forms a part of the effective registration statement.
- A preliminary prospectus relating to the public offering has been filed with the SEC and is available on the SEC's website located at http://www.sec.gov .
MIAMI, March 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today that the Company’s Board of Directors has approved a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (the “common stock”) (the “Reverse Split”).
Key Points:
- MIAMI, March 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today that the Company’s Board of Directors has approved a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (the “common stock”) (the “Reverse Split”).
- The Reverse Split was previously approved by the Company’s stockholders at a special meeting held on February 21, 2024 The Reverse Split will legally take effect at 11:59 p.m. Eastern Time, on March 26, 2024.
- The Reverse Split will automatically convert every ten current shares of the Company’s common stock, whether issued and outstanding or held by the Company as treasury stock, into one share of fully paid and nonassessable common stock.
- Stockholders owning shares through a bank, broker, or other nominee will have their positions automatically adjusted to reflect the Reverse Split, subject to brokers’ particular processes, and will not be required to take any action in connection with the Reverse Split.
Retrieved on:
Tuesday, February 27, 2024
American Heart Association,
Conference call,
ARIA,
Hypoplastic left heart syndrome,
Completion,
Conference,
American Heart,
Patient,
Clinical trial,
Survival,
Poster,
Mortality,
CADS,
Pharmaceutical industry Grant revenue for the years ended December 31, 2023 and 2022 was less than $0.1 million and $0.3 million, respectively.
Key Points:
- Grant revenue for the years ended December 31, 2023 and 2022 was less than $0.1 million and $0.3 million, respectively.
- Other Expense (Income), net: Other expense for the years ended December 31, 2023 and 2023 was $0.4 million and $0.8 million, respectively.
- Other expense for 2023 decreased mainly as a result of non-operating lawsuit expenses of $1.4 million in 2022, compared to less than $0.1 million in 2023.
- ET to discuss the Company’s third quarter 2023 financial results and provide a business update.
